Evidence map›Paper›PMID 38819656›Full record

ArticleArchives of dermatological research2024

Lipid traits and lipid-lowering drug target genes and risk of melanoma: a mendelian randomization study.

Yuhui Che, Jinyao Yuan, Dadong Tang, Jing Guo

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuhui CheHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jinyao YuanWest China Second Hospital of Sichuan University, Chengdu, China.
Dadong TangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jing GuoHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. guojing66@cdutcm.edu.cn.

Funding

Chengdu University of Traditional Chinese Medicine "Foundation Thickening" action plan grant number 2023-42Chengdu University of Traditional Chinese Medicine Hospital "100 People Program" 21-L03 and 22-B09Chengdu University of Traditional Chinese Medicine "Xing Lin Scholars" discipline talent Research Promotion Program QJJJ2021001National Natural Sciences Foundation of China 82074443Science and Technology Research Project of Sichuan Administration of Traditional Chinese Medicine 22CP1423Sichuan Provincial Administration of Traditional Chinese Medicine 2021MS307"Young Qi Huang Scholar" of State Administration of Traditional Chinese Medicine 2022-256
6 · The paper itself

Abstract

Our study aimed to investigate the role of lipids in melanoma risk and the effect of lipid-lowering drug targets on melanoma. Using Mendelian Randomization analysis, we examined the genetic agents of nine lipid-lowering drugs and their association with melanoma risk. We found that genetically proxied inhibition of HMGCR, ABCG5/ABCG8, and ANGPTL3 was associated with a reduced risk of melanoma. On the other hand, inhibition of LPL and Apo-B100 was significantly associated with an increased risk of melanoma. Sensitivity analyses did not reveal any statistical evidence of bias from pleiotropy or genetic confounding. We did not find a robust association between lipid traits NPC1L1, PCSK9, APOC3 inhibition, and melanoma risk. These findings were validated using two independent lipid datasets. Our analysis also revealed that HMGCR, ANGPTL3, and ABCG5/ABCG8 inhibitors reduced melanoma risk independent of their effects on lipids. This suggests that these targets may have potential for melanoma prevention or treatment. In conclusion, our study provides evidence for a causal role of lipids in melanoma risk and highlights specific lipid-lowering drug targets that may be effective in reducing the risk of melanoma. These findings contribute to the understanding of the underlying mechanisms of melanoma development and provide potential avenues for further research and therapeutic interventions.

Indexed as

Angiopoietin-Like Protein 3ATP Binding Cassette Transporter, Subfamily G, Member 5Hypolipidemic AgentsMelanomaMendelian Randomization AnalysisSkin NeoplasmsAngiopoietin-like ProteinsApolipoprotein B-100ATP Binding Cassette Transporter, Subfamily G, Member 8Genetic Predisposition to DiseaseHumansHydroxymethylglutaryl CoA ReductasesLipid MetabolismLipoprotein LipaseLipoproteinsPolymorphism, Single NucleotideABCG5 protein, humanABCG8 protein, humanAngiopoietin-Like Protein 3Angiopoietin-like ProteinsANGPTL3 protein, humanApolipoprotein B-100ATP Binding Cassette Transporter, Subfamily G, Member 5ATP Binding Cassette Transporter, Subfamily G, Member 8HMGCR protein, humanHydroxymethylglutaryl CoA ReductasesHypolipidemic AgentsLipoprotein LipaseLipoproteinsLPL protein, humanLipid-lowering drugsLipidsMelanomaMendelian randomizationRisk

Identifiers

PMID38819656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.